Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong speaks to Christian Leisner, Chief Executive Officer of antibody therapeutics' developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Why are existing immunotherapies restricted to certain patient populations? CL: Immunotherapies, principally anti-PD-1/-L1 checkpoint inhibitors, have shown therapeutic benefit in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!